{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 124,
   "metadata": {},
   "outputs": [],
   "source": [
    "import numpy as np\n",
    "import pandas as pd\n",
    "import seaborn as sns\n",
    "import matplotlib.pyplot as plt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 125,
   "metadata": {},
   "outputs": [],
   "source": [
    "pd.set_option('display.max_colwidth', None)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 126,
   "metadata": {},
   "outputs": [],
   "source": [
    "df1 = pd.read_csv(\"../data/bert_scores/BERT_similarity1.csv\", sep=',')\n",
    "df2 = pd.read_csv(\"../data/bert_scores/BERT_similarity2.csv\", sep=',')\n",
    "df3 = pd.read_csv(\"../data/bert_scores/BERT_similarity3.csv\", sep=',')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 127,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>score</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>14466574</td>\n",
       "      <td>0.839626</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>23812236</td>\n",
       "      <td>0.366735</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>11834247</td>\n",
       "      <td>0.550217</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>30649221</td>\n",
       "      <td>0.719352</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>25824079</td>\n",
       "      <td>0.713064</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>280981</th>\n",
       "      <td>3821855</td>\n",
       "      <td>0.771915</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>280982</th>\n",
       "      <td>20622458</td>\n",
       "      <td>0.878476</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>280983</th>\n",
       "      <td>36160198</td>\n",
       "      <td>0.822413</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>280984</th>\n",
       "      <td>5426867</td>\n",
       "      <td>0.765264</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>280985</th>\n",
       "      <td>3548782</td>\n",
       "      <td>0.838007</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>842954 rows × 2 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "              id     score\n",
       "0       14466574  0.839626\n",
       "1       23812236  0.366735\n",
       "2       11834247  0.550217\n",
       "3       30649221  0.719352\n",
       "4       25824079  0.713064\n",
       "...          ...       ...\n",
       "280981   3821855  0.771915\n",
       "280982  20622458  0.878476\n",
       "280983  36160198  0.822413\n",
       "280984   5426867  0.765264\n",
       "280985   3548782  0.838007\n",
       "\n",
       "[842954 rows x 2 columns]"
      ]
     },
     "execution_count": 127,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "frames = [df1, df2, df3]\n",
    "df = pd.concat(frames)\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 128,
   "metadata": {},
   "outputs": [],
   "source": [
    "data = df.copy()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 129,
   "metadata": {},
   "outputs": [],
   "source": [
    "sentences = pd.read_csv(\"../data/medical_corpus_clean_preprocessed_v2.tsv\", sep=',')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 130,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>score</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>count</th>\n",
       "      <td>8.429540e+05</td>\n",
       "      <td>842954.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>mean</th>\n",
       "      <td>1.972107e+07</td>\n",
       "      <td>0.773491</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>std</th>\n",
       "      <td>1.138195e+07</td>\n",
       "      <td>0.186604</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>min</th>\n",
       "      <td>2.900000e+01</td>\n",
       "      <td>-0.172695</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25%</th>\n",
       "      <td>9.881131e+06</td>\n",
       "      <td>0.738111</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50%</th>\n",
       "      <td>1.971656e+07</td>\n",
       "      <td>0.829918</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75%</th>\n",
       "      <td>2.956373e+07</td>\n",
       "      <td>0.880051</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>max</th>\n",
       "      <td>3.944201e+07</td>\n",
       "      <td>1.000001</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                 id          score\n",
       "count  8.429540e+05  842954.000000\n",
       "mean   1.972107e+07       0.773491\n",
       "std    1.138195e+07       0.186604\n",
       "min    2.900000e+01      -0.172695\n",
       "25%    9.881131e+06       0.738111\n",
       "50%    1.971656e+07       0.829918\n",
       "75%    2.956373e+07       0.880051\n",
       "max    3.944201e+07       1.000001"
      ]
     },
     "execution_count": 130,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.describe()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "The cosine similarity should be between -1 and 1. To obtain cosine similarities, I used the library 'from sklearn.metrics.pairwise import cosine_similarity'. However, it sometimes generated values greater than 1 due to floating-point precision errors. To address this issue, I set those values that were greater than 1 to be equal to 1."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 131,
   "metadata": {},
   "outputs": [],
   "source": [
    "df.loc[df['score'] > 1, 'score'] = 1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 132,
   "metadata": {},
   "outputs": [],
   "source": [
    "similiraty_list = df.score.to_list()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 133,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>score</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>count</th>\n",
       "      <td>8.429540e+05</td>\n",
       "      <td>842954.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>mean</th>\n",
       "      <td>1.972107e+07</td>\n",
       "      <td>0.773491</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>std</th>\n",
       "      <td>1.138195e+07</td>\n",
       "      <td>0.186604</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>min</th>\n",
       "      <td>2.900000e+01</td>\n",
       "      <td>-0.172695</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25%</th>\n",
       "      <td>9.881131e+06</td>\n",
       "      <td>0.738111</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50%</th>\n",
       "      <td>1.971656e+07</td>\n",
       "      <td>0.829918</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75%</th>\n",
       "      <td>2.956373e+07</td>\n",
       "      <td>0.880051</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>max</th>\n",
       "      <td>3.944201e+07</td>\n",
       "      <td>1.000000</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                 id          score\n",
       "count  8.429540e+05  842954.000000\n",
       "mean   1.972107e+07       0.773491\n",
       "std    1.138195e+07       0.186604\n",
       "min    2.900000e+01      -0.172695\n",
       "25%    9.881131e+06       0.738111\n",
       "50%    1.971656e+07       0.829918\n",
       "75%    2.956373e+07       0.880051\n",
       "max    3.944201e+07       1.000000"
      ]
     },
     "execution_count": 133,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.describe()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 134,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>score</th>\n",
       "      <th>pol</th>\n",
       "      <th>eng</th>\n",
       "      <th>split</th>\n",
       "      <th>src</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>14466574</td>\n",
       "      <td>0.839626</td>\n",
       "      <td>Urządzenia do odtworzenia i podawania dostarczane są w każdym opakowaniu Helixate NexGen 250 j. m.</td>\n",
       "      <td>Medical devices for reconstitution and administration are provided with each package of Helixate NexGen 250 IU.</td>\n",
       "      <td>train</td>\n",
       "      <td>EMEA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>23812236</td>\n",
       "      <td>0.366735</td>\n",
       "      <td>DOTYCZĄCE DOSTAWY I STOSOWANIA</td>\n",
       "      <td>Veterinary medicinal product subject to prescription.</td>\n",
       "      <td>train</td>\n",
       "      <td>EMEA_new_crawl</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>11834247</td>\n",
       "      <td>0.550217</td>\n",
       "      <td>51 jeśli u pacjenta wystąpi ból górnej części brzucha po lewej stronie lub ból na szczycie barku; •</td>\n",
       "      <td>• if you get left upper abdominal pain or pain at the tip of your shoulder;</td>\n",
       "      <td>train</td>\n",
       "      <td>EMEA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>30649221</td>\n",
       "      <td>0.719352</td>\n",
       "      <td>Wydłużenie czasu protrombinowego (PT) (w przypadku jednoczesnego stosowania antagonistów witaminy K).</td>\n",
       "      <td>Prothrombin time (PT) increase (with concomitant vitamin K antagonist therapy).</td>\n",
       "      <td>train</td>\n",
       "      <td>EMEA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>25824079</td>\n",
       "      <td>0.713064</td>\n",
       "      <td>Zaburzenia serca</td>\n",
       "      <td>Eye disorders Cardiac disorders</td>\n",
       "      <td>train</td>\n",
       "      <td>EMEA_new_crawl</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>842949</th>\n",
       "      <td>3821855</td>\n",
       "      <td>0.771915</td>\n",
       "      <td>Zmiany obecne po 1 miesiącu podawania produktu były zasadniczo odwracalne w czasie do 1 miesiąca po zaprzestaniu podawania produktu, za wyjątkiem częściowego ustąpienia niektórych zmian w rogówce.</td>\n",
       "      <td>The findings present following 1 month of dosing were largely reversible within 1 month of cessation of dosing with the exception of partial recovery for some of the corneal changes.</td>\n",
       "      <td>test</td>\n",
       "      <td>EMEA_new_crawl</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>842950</th>\n",
       "      <td>20622458</td>\n",
       "      <td>0.878476</td>\n",
       "      <td>Delikatnie postukać w strzykawkę, aby usunąć pęcherzyki powietrza.</td>\n",
       "      <td>To remove any bubbles, gently tap the syringe.</td>\n",
       "      <td>test</td>\n",
       "      <td>EMEA_new_crawl</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>842951</th>\n",
       "      <td>36160198</td>\n",
       "      <td>0.822413</td>\n",
       "      <td>dorosłych pacjentów z nowo rozpoznaną ostrą białaczką limfoblastyczną z chromosomem Philadelphia (Ph+ ALL) w skojarzeniu z chemioterapią.</td>\n",
       "      <td>adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.</td>\n",
       "      <td>test</td>\n",
       "      <td>EMEA_new_crawl</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>842952</th>\n",
       "      <td>5426867</td>\n",
       "      <td>0.765264</td>\n",
       "      <td>Podczas stosowania przewlekłego w badaniu RE–LY leki z grupy NLPZ zwiększały ryzyko krwawienia o około 50% zarówno w przypadku eteksylanu dabigatranu, jak i warfaryny.</td>\n",
       "      <td>With chronic use in the RE-LY study, NSAIDs increased the risk of bleeding by approximately 50 % on both dabigatran etexilate and warfarin.</td>\n",
       "      <td>test</td>\n",
       "      <td>EMEA_new_crawl</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>842953</th>\n",
       "      <td>3548782</td>\n",
       "      <td>0.838007</td>\n",
       "      <td>Jak przechowywać lek Tamiflu</td>\n",
       "      <td>Each hard capsule contains oseltamivir equivalent to 75 mg of oseltamivir The other ingredients are: capsule contents: pregelatinised starch, talc, povidone, croscarmellose sodium and sodium stearyl fumarate capsule shell: gelatin, yellow iron oxide (E172), red iron oxide (E172), black iron oxide (E172) and titanium dioxide (E171) printing ink: shellac (E904), titanium dioxide (E171) FD and C Blue 2 (indigo carmine E132).</td>\n",
       "      <td>test</td>\n",
       "      <td>EMEA_new_crawl</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>842954 rows × 6 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "              id     score  \\\n",
       "0       14466574  0.839626   \n",
       "1       23812236  0.366735   \n",
       "2       11834247  0.550217   \n",
       "3       30649221  0.719352   \n",
       "4       25824079  0.713064   \n",
       "...          ...       ...   \n",
       "842949   3821855  0.771915   \n",
       "842950  20622458  0.878476   \n",
       "842951  36160198  0.822413   \n",
       "842952   5426867  0.765264   \n",
       "842953   3548782  0.838007   \n",
       "\n",
       "                                                                                                                                                                                                         pol  \\\n",
       "0                                                                                                         Urządzenia do odtworzenia i podawania dostarczane są w każdym opakowaniu Helixate NexGen 250 j. m.   \n",
       "1                                                                                                                                                                             DOTYCZĄCE DOSTAWY I STOSOWANIA   \n",
       "2                                                                                                        51 jeśli u pacjenta wystąpi ból górnej części brzucha po lewej stronie lub ból na szczycie barku; •   \n",
       "3                                                                                                      Wydłużenie czasu protrombinowego (PT) (w przypadku jednoczesnego stosowania antagonistów witaminy K).   \n",
       "4                                                                                                                                                                                           Zaburzenia serca   \n",
       "...                                                                                                                                                                                                      ...   \n",
       "842949  Zmiany obecne po 1 miesiącu podawania produktu były zasadniczo odwracalne w czasie do 1 miesiąca po zaprzestaniu podawania produktu, za wyjątkiem częściowego ustąpienia niektórych zmian w rogówce.   \n",
       "842950                                                                                                                                    Delikatnie postukać w strzykawkę, aby usunąć pęcherzyki powietrza.   \n",
       "842951                                                             dorosłych pacjentów z nowo rozpoznaną ostrą białaczką limfoblastyczną z chromosomem Philadelphia (Ph+ ALL) w skojarzeniu z chemioterapią.   \n",
       "842952                               Podczas stosowania przewlekłego w badaniu RE–LY leki z grupy NLPZ zwiększały ryzyko krwawienia o około 50% zarówno w przypadku eteksylanu dabigatranu, jak i warfaryny.   \n",
       "842953                                                                                                                                                                          Jak przechowywać lek Tamiflu   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                              eng  \\\n",
       "0                                                                                                                                                                                                                                                                                                                                 Medical devices for reconstitution and administration are provided with each package of Helixate NexGen 250 IU.   \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                           Veterinary medicinal product subject to prescription.   \n",
       "2                                                                                                                                                                                                                                                                                                                                                                     • if you get left upper abdominal pain or pain at the tip of your shoulder;   \n",
       "3                                                                                                                                                                                                                                                                                                                                                                 Prothrombin time (PT) increase (with concomitant vitamin K antagonist therapy).   \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                                 Eye disorders Cardiac disorders   \n",
       "...                                                                                                                                                                                                                                                                                                                                                                                                                                           ...   \n",
       "842949                                                                                                                                                                                                                                                     The findings present following 1 month of dosing were largely reversible within 1 month of cessation of dosing with the exception of partial recovery for some of the corneal changes.   \n",
       "842950                                                                                                                                                                                                                                                                                                                                                                                             To remove any bubbles, gently tap the syringe.   \n",
       "842951                                                                                                                                                                                                                                                                                                 adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.   \n",
       "842952                                                                                                                                                                                                                                                                                                With chronic use in the RE-LY study, NSAIDs increased the risk of bleeding by approximately 50 % on both dabigatran etexilate and warfarin.   \n",
       "842953  Each hard capsule contains oseltamivir equivalent to 75 mg of oseltamivir The other ingredients are: capsule contents: pregelatinised starch, talc, povidone, croscarmellose sodium and sodium stearyl fumarate capsule shell: gelatin, yellow iron oxide (E172), red iron oxide (E172), black iron oxide (E172) and titanium dioxide (E171) printing ink: shellac (E904), titanium dioxide (E171) FD and C Blue 2 (indigo carmine E132).   \n",
       "\n",
       "        split             src  \n",
       "0       train            EMEA  \n",
       "1       train  EMEA_new_crawl  \n",
       "2       train            EMEA  \n",
       "3       train            EMEA  \n",
       "4       train  EMEA_new_crawl  \n",
       "...       ...             ...  \n",
       "842949   test  EMEA_new_crawl  \n",
       "842950   test  EMEA_new_crawl  \n",
       "842951   test  EMEA_new_crawl  \n",
       "842952   test  EMEA_new_crawl  \n",
       "842953   test  EMEA_new_crawl  \n",
       "\n",
       "[842954 rows x 6 columns]"
      ]
     },
     "execution_count": 134,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data = pd.merge(data, sentences, on='id')\n",
    "data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 135,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "sns.histplot(similiraty_list, bins=100, color='blue', edgecolor='black')\n",
    "plt.title('Bert scores distributions')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 136,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "sns.boxplot(x=df[\"score\"])\n",
    "plt.title('BERT scores')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 137,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The median of the scores is: 0.82991779\n"
     ]
    }
   ],
   "source": [
    "median_value = df['score'].median()\n",
    "print(f\"The median of the scores is: {median_value}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 138,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>score</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "Empty DataFrame\n",
       "Columns: [id, score]\n",
       "Index: []"
      ]
     },
     "execution_count": 138,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_nan_scores = df[df['score'].isna()]\n",
    "df_nan_scores"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 139,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>score</th>\n",
       "      <th>pol</th>\n",
       "      <th>eng</th>\n",
       "      <th>split</th>\n",
       "      <th>src</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>14466574</td>\n",
       "      <td>0.839626</td>\n",
       "      <td>Urządzenia do odtworzenia i podawania dostarczane są w każdym opakowaniu Helixate NexGen 250 j. m.</td>\n",
       "      <td>Medical devices for reconstitution and administration are provided with each package of Helixate NexGen 250 IU.</td>\n",
       "      <td>train</td>\n",
       "      <td>EMEA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>30513235</td>\n",
       "      <td>0.869715</td>\n",
       "      <td>W takim przypadku należy odstąpić od podawania hCG aby uniknąć wystąpienia ciąży mnogiej. • Kontrolowana hiperstymulacja jajników w medycznych programach wspomaganego rozrodu Stosuje się różne protokoły stymulacji.</td>\n",
       "      <td>In that case hCG should be withheld and pregnancy should be avoided in order to prevent multiple gestations. • Controlled ovarian hyperstimulation in medically assisted reproduction programs Various stimulation protocols are applied.</td>\n",
       "      <td>train</td>\n",
       "      <td>EMEA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>29354410</td>\n",
       "      <td>0.874398</td>\n",
       "      <td>Każda fiolka jednorazowego użytku zawiera 160 mg proszku do sporządzenia 8 ml koncentratu roztworu trastuzumabu emtanzyny do infuzji o stężeniu 20 mg/ml.</td>\n",
       "      <td>deliver 8 ml of 20 mg/ml of trastuzumab emtansine.</td>\n",
       "      <td>train</td>\n",
       "      <td>EMEA_new_crawl</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>22229922</td>\n",
       "      <td>0.852618</td>\n",
       "      <td>4.7 Wpływ na zdolność prowadzenia pojazdów i obsługiwania maszyn</td>\n",
       "      <td>4.7 Effects on ability to drive and use machines</td>\n",
       "      <td>train</td>\n",
       "      <td>EMEA_new_crawl</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>34330160</td>\n",
       "      <td>0.905408</td>\n",
       "      <td>4. 5 Interakcje z innymi lekami i inne rodzaje interakcji</td>\n",
       "      <td>4.5 Interaction with other medicinal products and other forms of interaction</td>\n",
       "      <td>train</td>\n",
       "      <td>EMEA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>842936</th>\n",
       "      <td>17979726</td>\n",
       "      <td>0.921728</td>\n",
       "      <td>W celu uzyskania dodatkowych informacji dotyczących leczenia produktem Mixtard należy zapoznać się z ulotką dla pacjenta (także część EPAR) bądź skontaktować się z lekarzem lub farmaceutą.</td>\n",
       "      <td>For more information about treatment with Mixtard, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.</td>\n",
       "      <td>test</td>\n",
       "      <td>EMEA_new_crawl</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>842943</th>\n",
       "      <td>12998604</td>\n",
       "      <td>0.907766</td>\n",
       "      <td>Co to jest lek Memantine Mylan i w jakim celu się go stosuje 2.</td>\n",
       "      <td>What Memantine Mylan is and what it is used for 2.</td>\n",
       "      <td>test</td>\n",
       "      <td>EMEA_new_crawl</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>842948</th>\n",
       "      <td>19426515</td>\n",
       "      <td>0.845784</td>\n",
       "      <td>Szczepionki nie powinno podawać się osobom z osłabionym układem odpornościowym, z powodu takich chorób jak białaczka, chłoniak, AIDS bądź chorób osłabiających układ odpornościowy.</td>\n",
       "      <td>The vaccine should not be used in people who have problems with their immune system, either because they have a disease such as leukaemia, lymphoma, AIDS, or because they are taking medicines that affect the immune system.</td>\n",
       "      <td>test</td>\n",
       "      <td>EMEA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>842950</th>\n",
       "      <td>20622458</td>\n",
       "      <td>0.878476</td>\n",
       "      <td>Delikatnie postukać w strzykawkę, aby usunąć pęcherzyki powietrza.</td>\n",
       "      <td>To remove any bubbles, gently tap the syringe.</td>\n",
       "      <td>test</td>\n",
       "      <td>EMEA_new_crawl</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>842953</th>\n",
       "      <td>3548782</td>\n",
       "      <td>0.838007</td>\n",
       "      <td>Jak przechowywać lek Tamiflu</td>\n",
       "      <td>Each hard capsule contains oseltamivir equivalent to 75 mg of oseltamivir The other ingredients are: capsule contents: pregelatinised starch, talc, povidone, croscarmellose sodium and sodium stearyl fumarate capsule shell: gelatin, yellow iron oxide (E172), red iron oxide (E172), black iron oxide (E172) and titanium dioxide (E171) printing ink: shellac (E904), titanium dioxide (E171) FD and C Blue 2 (indigo carmine E132).</td>\n",
       "      <td>test</td>\n",
       "      <td>EMEA_new_crawl</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>421211 rows × 6 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "              id     score  \\\n",
       "0       14466574  0.839626   \n",
       "5       30513235  0.869715   \n",
       "6       29354410  0.874398   \n",
       "7       22229922  0.852618   \n",
       "9       34330160  0.905408   \n",
       "...          ...       ...   \n",
       "842936  17979726  0.921728   \n",
       "842943  12998604  0.907766   \n",
       "842948  19426515  0.845784   \n",
       "842950  20622458  0.878476   \n",
       "842953   3548782  0.838007   \n",
       "\n",
       "                                                                                                                                                                                                                           pol  \\\n",
       "0                                                                                                                           Urządzenia do odtworzenia i podawania dostarczane są w każdym opakowaniu Helixate NexGen 250 j. m.   \n",
       "5       W takim przypadku należy odstąpić od podawania hCG aby uniknąć wystąpienia ciąży mnogiej. • Kontrolowana hiperstymulacja jajników w medycznych programach wspomaganego rozrodu Stosuje się różne protokoły stymulacji.   \n",
       "6                                                                    Każda fiolka jednorazowego użytku zawiera 160 mg proszku do sporządzenia 8 ml koncentratu roztworu trastuzumabu emtanzyny do infuzji o stężeniu 20 mg/ml.   \n",
       "7                                                                                                                                                             4.7 Wpływ na zdolność prowadzenia pojazdów i obsługiwania maszyn   \n",
       "9                                                                                                                                                                    4. 5 Interakcje z innymi lekami i inne rodzaje interakcji   \n",
       "...                                                                                                                                                                                                                        ...   \n",
       "842936                            W celu uzyskania dodatkowych informacji dotyczących leczenia produktem Mixtard należy zapoznać się z ulotką dla pacjenta (także część EPAR) bądź skontaktować się z lekarzem lub farmaceutą.   \n",
       "842943                                                                                                                                                         Co to jest lek Memantine Mylan i w jakim celu się go stosuje 2.   \n",
       "842948                                     Szczepionki nie powinno podawać się osobom z osłabionym układem odpornościowym, z powodu takich chorób jak białaczka, chłoniak, AIDS bądź chorób osłabiających układ odpornościowy.   \n",
       "842950                                                                                                                                                      Delikatnie postukać w strzykawkę, aby usunąć pęcherzyki powietrza.   \n",
       "842953                                                                                                                                                                                            Jak przechowywać lek Tamiflu   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                              eng  \\\n",
       "0                                                                                                                                                                                                                                                                                                                                 Medical devices for reconstitution and administration are provided with each package of Helixate NexGen 250 IU.   \n",
       "5                                                                                                                                                                                                       In that case hCG should be withheld and pregnancy should be avoided in order to prevent multiple gestations. • Controlled ovarian hyperstimulation in medically assisted reproduction programs Various stimulation protocols are applied.   \n",
       "6                                                                                                                                                                                                                                                                                                                                                                                              deliver 8 ml of 20 mg/ml of trastuzumab emtansine.   \n",
       "7                                                                                                                                                                                                                                                                                                                                                                                                4.7 Effects on ability to drive and use machines   \n",
       "9                                                                                                                                                                                                                                                                                                                                                                    4.5 Interaction with other medicinal products and other forms of interaction   \n",
       "...                                                                                                                                                                                                                                                                                                                                                                                                                                           ...   \n",
       "842936                                                                                                                                                                                                                                                                                                  For more information about treatment with Mixtard, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.   \n",
       "842943                                                                                                                                                                                                                                                                                                                                                                                         What Memantine Mylan is and what it is used for 2.   \n",
       "842948                                                                                                                                                                                                             The vaccine should not be used in people who have problems with their immune system, either because they have a disease such as leukaemia, lymphoma, AIDS, or because they are taking medicines that affect the immune system.   \n",
       "842950                                                                                                                                                                                                                                                                                                                                                                                             To remove any bubbles, gently tap the syringe.   \n",
       "842953  Each hard capsule contains oseltamivir equivalent to 75 mg of oseltamivir The other ingredients are: capsule contents: pregelatinised starch, talc, povidone, croscarmellose sodium and sodium stearyl fumarate capsule shell: gelatin, yellow iron oxide (E172), red iron oxide (E172), black iron oxide (E172) and titanium dioxide (E171) printing ink: shellac (E904), titanium dioxide (E171) FD and C Blue 2 (indigo carmine E132).   \n",
       "\n",
       "        split             src  \n",
       "0       train            EMEA  \n",
       "5       train            EMEA  \n",
       "6       train  EMEA_new_crawl  \n",
       "7       train  EMEA_new_crawl  \n",
       "9       train            EMEA  \n",
       "...       ...             ...  \n",
       "842936   test  EMEA_new_crawl  \n",
       "842943   test  EMEA_new_crawl  \n",
       "842948   test            EMEA  \n",
       "842950   test  EMEA_new_crawl  \n",
       "842953   test  EMEA_new_crawl  \n",
       "\n",
       "[421211 rows x 6 columns]"
      ]
     },
     "execution_count": 139,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_good_scores = data[data['score'] > 0.83]\n",
    "df_good_scores"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 140,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>score</th>\n",
       "      <th>pol</th>\n",
       "      <th>eng</th>\n",
       "      <th>split</th>\n",
       "      <th>src</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>14466574</td>\n",
       "      <td>0.839626</td>\n",
       "      <td>Urządzenia do odtworzenia i podawania dostarczane są w każdym opakowaniu Helixate NexGen 250 j. m.</td>\n",
       "      <td>Medical devices for reconstitution and administration are provided with each package of Helixate NexGen 250 IU.</td>\n",
       "      <td>train</td>\n",
       "      <td>EMEA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>30513235</td>\n",
       "      <td>0.869715</td>\n",
       "      <td>W takim przypadku należy odstąpić od podawania hCG aby uniknąć wystąpienia ciąży mnogiej. • Kontrolowana hiperstymulacja jajników w medycznych programach wspomaganego rozrodu Stosuje się różne protokoły stymulacji.</td>\n",
       "      <td>In that case hCG should be withheld and pregnancy should be avoided in order to prevent multiple gestations. • Controlled ovarian hyperstimulation in medically assisted reproduction programs Various stimulation protocols are applied.</td>\n",
       "      <td>train</td>\n",
       "      <td>EMEA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>29354410</td>\n",
       "      <td>0.874398</td>\n",
       "      <td>Każda fiolka jednorazowego użytku zawiera 160 mg proszku do sporządzenia 8 ml koncentratu roztworu trastuzumabu emtanzyny do infuzji o stężeniu 20 mg/ml.</td>\n",
       "      <td>deliver 8 ml of 20 mg/ml of trastuzumab emtansine.</td>\n",
       "      <td>train</td>\n",
       "      <td>EMEA_new_crawl</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>22229922</td>\n",
       "      <td>0.852618</td>\n",
       "      <td>4.7 Wpływ na zdolność prowadzenia pojazdów i obsługiwania maszyn</td>\n",
       "      <td>4.7 Effects on ability to drive and use machines</td>\n",
       "      <td>train</td>\n",
       "      <td>EMEA_new_crawl</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>34330160</td>\n",
       "      <td>0.905408</td>\n",
       "      <td>4. 5 Interakcje z innymi lekami i inne rodzaje interakcji</td>\n",
       "      <td>4.5 Interaction with other medicinal products and other forms of interaction</td>\n",
       "      <td>train</td>\n",
       "      <td>EMEA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>842936</th>\n",
       "      <td>17979726</td>\n",
       "      <td>0.921728</td>\n",
       "      <td>W celu uzyskania dodatkowych informacji dotyczących leczenia produktem Mixtard należy zapoznać się z ulotką dla pacjenta (także część EPAR) bądź skontaktować się z lekarzem lub farmaceutą.</td>\n",
       "      <td>For more information about treatment with Mixtard, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.</td>\n",
       "      <td>test</td>\n",
       "      <td>EMEA_new_crawl</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>842943</th>\n",
       "      <td>12998604</td>\n",
       "      <td>0.907766</td>\n",
       "      <td>Co to jest lek Memantine Mylan i w jakim celu się go stosuje 2.</td>\n",
       "      <td>What Memantine Mylan is and what it is used for 2.</td>\n",
       "      <td>test</td>\n",
       "      <td>EMEA_new_crawl</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>842948</th>\n",
       "      <td>19426515</td>\n",
       "      <td>0.845784</td>\n",
       "      <td>Szczepionki nie powinno podawać się osobom z osłabionym układem odpornościowym, z powodu takich chorób jak białaczka, chłoniak, AIDS bądź chorób osłabiających układ odpornościowy.</td>\n",
       "      <td>The vaccine should not be used in people who have problems with their immune system, either because they have a disease such as leukaemia, lymphoma, AIDS, or because they are taking medicines that affect the immune system.</td>\n",
       "      <td>test</td>\n",
       "      <td>EMEA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>842950</th>\n",
       "      <td>20622458</td>\n",
       "      <td>0.878476</td>\n",
       "      <td>Delikatnie postukać w strzykawkę, aby usunąć pęcherzyki powietrza.</td>\n",
       "      <td>To remove any bubbles, gently tap the syringe.</td>\n",
       "      <td>test</td>\n",
       "      <td>EMEA_new_crawl</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>842953</th>\n",
       "      <td>3548782</td>\n",
       "      <td>0.838007</td>\n",
       "      <td>Jak przechowywać lek Tamiflu</td>\n",
       "      <td>Each hard capsule contains oseltamivir equivalent to 75 mg of oseltamivir The other ingredients are: capsule contents: pregelatinised starch, talc, povidone, croscarmellose sodium and sodium stearyl fumarate capsule shell: gelatin, yellow iron oxide (E172), red iron oxide (E172), black iron oxide (E172) and titanium dioxide (E171) printing ink: shellac (E904), titanium dioxide (E171) FD and C Blue 2 (indigo carmine E132).</td>\n",
       "      <td>test</td>\n",
       "      <td>EMEA_new_crawl</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>421211 rows × 6 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "              id     score  \\\n",
       "0       14466574  0.839626   \n",
       "5       30513235  0.869715   \n",
       "6       29354410  0.874398   \n",
       "7       22229922  0.852618   \n",
       "9       34330160  0.905408   \n",
       "...          ...       ...   \n",
       "842936  17979726  0.921728   \n",
       "842943  12998604  0.907766   \n",
       "842948  19426515  0.845784   \n",
       "842950  20622458  0.878476   \n",
       "842953   3548782  0.838007   \n",
       "\n",
       "                                                                                                                                                                                                                           pol  \\\n",
       "0                                                                                                                           Urządzenia do odtworzenia i podawania dostarczane są w każdym opakowaniu Helixate NexGen 250 j. m.   \n",
       "5       W takim przypadku należy odstąpić od podawania hCG aby uniknąć wystąpienia ciąży mnogiej. • Kontrolowana hiperstymulacja jajników w medycznych programach wspomaganego rozrodu Stosuje się różne protokoły stymulacji.   \n",
       "6                                                                    Każda fiolka jednorazowego użytku zawiera 160 mg proszku do sporządzenia 8 ml koncentratu roztworu trastuzumabu emtanzyny do infuzji o stężeniu 20 mg/ml.   \n",
       "7                                                                                                                                                             4.7 Wpływ na zdolność prowadzenia pojazdów i obsługiwania maszyn   \n",
       "9                                                                                                                                                                    4. 5 Interakcje z innymi lekami i inne rodzaje interakcji   \n",
       "...                                                                                                                                                                                                                        ...   \n",
       "842936                            W celu uzyskania dodatkowych informacji dotyczących leczenia produktem Mixtard należy zapoznać się z ulotką dla pacjenta (także część EPAR) bądź skontaktować się z lekarzem lub farmaceutą.   \n",
       "842943                                                                                                                                                         Co to jest lek Memantine Mylan i w jakim celu się go stosuje 2.   \n",
       "842948                                     Szczepionki nie powinno podawać się osobom z osłabionym układem odpornościowym, z powodu takich chorób jak białaczka, chłoniak, AIDS bądź chorób osłabiających układ odpornościowy.   \n",
       "842950                                                                                                                                                      Delikatnie postukać w strzykawkę, aby usunąć pęcherzyki powietrza.   \n",
       "842953                                                                                                                                                                                            Jak przechowywać lek Tamiflu   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                              eng  \\\n",
       "0                                                                                                                                                                                                                                                                                                                                 Medical devices for reconstitution and administration are provided with each package of Helixate NexGen 250 IU.   \n",
       "5                                                                                                                                                                                                       In that case hCG should be withheld and pregnancy should be avoided in order to prevent multiple gestations. • Controlled ovarian hyperstimulation in medically assisted reproduction programs Various stimulation protocols are applied.   \n",
       "6                                                                                                                                                                                                                                                                                                                                                                                              deliver 8 ml of 20 mg/ml of trastuzumab emtansine.   \n",
       "7                                                                                                                                                                                                                                                                                                                                                                                                4.7 Effects on ability to drive and use machines   \n",
       "9                                                                                                                                                                                                                                                                                                                                                                    4.5 Interaction with other medicinal products and other forms of interaction   \n",
       "...                                                                                                                                                                                                                                                                                                                                                                                                                                           ...   \n",
       "842936                                                                                                                                                                                                                                                                                                  For more information about treatment with Mixtard, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.   \n",
       "842943                                                                                                                                                                                                                                                                                                                                                                                         What Memantine Mylan is and what it is used for 2.   \n",
       "842948                                                                                                                                                                                                             The vaccine should not be used in people who have problems with their immune system, either because they have a disease such as leukaemia, lymphoma, AIDS, or because they are taking medicines that affect the immune system.   \n",
       "842950                                                                                                                                                                                                                                                                                                                                                                                             To remove any bubbles, gently tap the syringe.   \n",
       "842953  Each hard capsule contains oseltamivir equivalent to 75 mg of oseltamivir The other ingredients are: capsule contents: pregelatinised starch, talc, povidone, croscarmellose sodium and sodium stearyl fumarate capsule shell: gelatin, yellow iron oxide (E172), red iron oxide (E172), black iron oxide (E172) and titanium dioxide (E171) printing ink: shellac (E904), titanium dioxide (E171) FD and C Blue 2 (indigo carmine E132).   \n",
       "\n",
       "        split             src  \n",
       "0       train            EMEA  \n",
       "5       train            EMEA  \n",
       "6       train  EMEA_new_crawl  \n",
       "7       train  EMEA_new_crawl  \n",
       "9       train            EMEA  \n",
       "...       ...             ...  \n",
       "842936   test  EMEA_new_crawl  \n",
       "842943   test  EMEA_new_crawl  \n",
       "842948   test            EMEA  \n",
       "842950   test  EMEA_new_crawl  \n",
       "842953   test  EMEA_new_crawl  \n",
       "\n",
       "[421211 rows x 6 columns]"
      ]
     },
     "execution_count": 140,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "negative_scores = data[data['score'] > 0.83]\n",
    "negative_scores"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 141,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Q1: 0.7070549, Q2: 0.802725484, Q3: 0.8520606, Q4: 0.8895534, Q5: 1.0\n"
     ]
    }
   ],
   "source": [
    "# Calculate quintiles using the quantile method\n",
    "q1 = df['score'].quantile(0.20)  # 20th percentile (first quintile)\n",
    "q2 = df['score'].quantile(0.40)  # 40th percentile (second quintile)\n",
    "q3 = df['score'].quantile(0.60)  # 60th percentile (third quintile)\n",
    "q4 = df['score'].quantile(0.80)  # 80th percentile (fourth quintile)\n",
    "q5 = df['score'].quantile(1.00)  # 100th percentile (fifth quintile)\n",
    "\n",
    "print(f'Q1: {q1}, Q2: {q2}, Q3: {q3}, Q4: {q4}, Q5: {q5}')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 142,
   "metadata": {},
   "outputs": [],
   "source": [
    "BERT_above_quantile_20 = df[df['score'] > q1]\n",
    "BERT_above_quantile_40 = df[df['score'] > q2]\n",
    "BERT_above_quantile_60 = df[df['score'] > q3]\n",
    "BERT_above_quantile_80 = df[df['score'] > q4]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 143,
   "metadata": {},
   "outputs": [],
   "source": [
    "BERT_above_quantile_20.to_csv(\"BERT_above_quantile_20.tsv\", sep='\\t', index=False)\n",
    "BERT_above_quantile_40.to_csv(\"BERT_above_quantile_40.tsv\", sep='\\t', index=False)\n",
    "BERT_above_quantile_60.to_csv(\"BERT_above_quantile_60.tsv\", sep='\\t', index=False)\n",
    "BERT_above_quantile_80.to_csv(\"BERT_above_quantile_80.tsv\", sep='\\t', index=False)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "project",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
